Arbutus Biopharma Corp Files 8-K on Director/Officer Changes

Ticker: ABUS · Form: 8-K · Filed: 2025-02-25T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes

TL;DR

Arbutus Biopharma is shuffling its board and officers, filing an 8-K on Feb 24th.

AI Summary

Arbutus Biopharma Corporation filed an 8-K on February 25, 2025, reporting on the departure of a director, the election of new directors, and the appointment of certain officers. The filing also covers compensatory arrangements for officers and other events. The company was formerly known as Tekmira Pharmaceuticals Corp.

Why It Matters

Changes in board composition and officer appointments can signal shifts in company strategy or governance, which are important for investors to monitor.

Risk Assessment

Risk Level: low — The filing primarily concerns routine corporate governance changes and does not appear to involve significant financial transactions or operational disruptions.

Key Players & Entities

Arbutus Biopharma Corporation (company) — Registrant
Tekmira Pharmaceuticals Corp (company) — Former company name
February 24, 2025 (date) — Date of earliest event reported
February 25, 2025 (date) — Date of report

FAQ

What specific items are being reported in this 8-K filing?

This 8-K filing reports on the departure of directors, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and other events.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on February 24, 2025.

What is the exact name of the registrant?

The exact name of the registrant is Arbutus Biopharma Corporation.

What was Arbutus Biopharma Corporation's former name?

Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.

What is the company's state of incorporation?

The company's state of incorporation is British Columbia, Canada.

From the Filing

0001171843-25-001049.txt : 20250225 0001171843-25-001049.hdr.sgml : 20250225 20250225070512 ACCESSION NUMBER: 0001171843-25-001049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250224 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 25659342 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_022525.htm FORM 8-K Form 8-K 0001447028 False 0001447028 2025-02-24 2025-02-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  February 24, 2025 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) _______________________________ British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 701 Veterans Circle Warminster , Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) ( 267 ) 469-0914 (Registrant's telephone number, including area code)   (Former name or former address, if changed since last report) _______________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, without par value ABUS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Directors On February 24, 2025, all of the members of the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) resigned from the Board a